

TOPSFIELD
Cancer Incidence by Sex, 1993 - 1997
Expected and Observed Case Counts, with Standardized Incidence Ratios

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|--|------------|------------|------------|---------------------------------------|------------|------------|------------|
| <u>Bladder, Urinary</u> | | | | <u>Melanoma of Skin</u> | | | |
| Male | 4.55 | 1 | NC* | Male | 2.64 | 5 | 190 |
| Female | 1.77 | 1 | NC* | Female | 2.03 | 5 | 246 |
| Total | 6.32 | 2 | NC* | Total | 4.67 | 10 | 214 #+ |
| <u>Brain and Other Central Nervous System</u> | | | | <u>Multiple Myeloma</u> | | | |
| Male | 1.40 | 0 | NC* | Male | 0.84 | 1 | NC* |
| Female | 1.19 | 2 | NC* | Female | 0.79 | 0 | NC* |
| Total | 2.59 | 2 | NC* | Total | 1.63 | 1 | NC* |
| <u>Breast</u> | | | | <u>Non-Hodgkin's Lymphoma</u> | | | |
| Male | 0.29 | 0 | NC* | Male | 3.46 | 1 | NC* |
| Female | 27.06 | 23 | 85 | Female | 3.11 | 3 | NC* |
| Total | 27.36 | 23 | 84 | Total | 6.57 | 4 | NC* |
| <u>Cervix Uteri</u> | | | | <u>Oral Cavity and Pharynx</u> | | | |
| Female | 1.57 | 0 | NC* | Male | 2.99 | 3 | NC* |
| | | | | Female | 1.42 | 1 | NC* |
| | | | | Total | 4.41 | 4 | NC* |
| <u>Colon / Rectum</u> | | | | <u>Ovary</u> | | | |
| Male | 11.47 | 6 | 52 | Female | 3.21 | 3 | NC* |
| Female | 11.32 | 7 | 62 | | | | |
| Total | 22.80 | 13 | 57 #- | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 1.68 | 1 | NC* | Male | 1.75 | 0 | NC* |
| Female | 0.58 | 0 | NC* | Female | 1.84 | 2 | NC* |
| Total | 2.26 | 1 | NC* | Total | 3.59 | 2 | NC* |
| <u>Hodgkin's Disease</u> | | | | <u>Prostate</u> | | | |
| Male | 0.59 | 0 | NC* | Male | 28.03 | 27 | 96 |
| Female | 0.45 | 0 | NC* | | | | |
| Total | 1.04 | 0 | NC* | | | | |
| <u>Kidney and Renal Pelvis</u> | | | | <u>Stomach</u> | | | |
| Male | 2.63 | 2 | NC* | Male | 1.97 | 1 | NC* |
| Female | 1.54 | 2 | NC* | Female | 1.22 | 1 | NC* |
| Total | 4.17 | 4 | NC* | Total | 3.19 | 2 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 1.63 | 2 | NC* | Male | 0.75 | 1 | NC* |

| | | | | | | | |
|---|-------|----|-------|---|--------|-----|-------|
| Female | 0.44 | 0 | NC* | | | | |
| Total | 2.07 | 2 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 1.88 | 0 | NC* | Male | 0.49 | 0 | NC* |
| Female | 1.45 | 2 | NC* | Female | 1.22 | 0 | NC* |
| Total | 3.33 | 2 | NC* | Total | 1.71 | 0 | NC* |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | <u>Uteri, Corpus and Uterus, NOS</u> | | | |
| Male | 0.91 | 0 | NC* | | | | |
| Female | 0.38 | 0 | NC* | Female | 5.25 | 6 | 114 |
| Total | 1.29 | 0 | NC* | | | | |
| <u>Lung and Bronchus</u> | | | | <u>All Sites / Types</u> | | | |
| Male | 14.69 | 5 | 34 ~- | Male | 90.71 | 58 | 64 ^- |
| Female | 10.77 | 6 | 56 | Female | 84.96 | 68 | 80 |
| Total | 25.46 | 11 | 43 ~- | Total | 175.67 | 126 | 72 ^- |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

indicates statistical significance at the $p \leq 0.05$ level

~ indicates statistical significance at the $p \leq 0.01$ level, as well as at the $p \leq 0.05$ level

^ indicates statistical significance at the $p \leq 0.001$ level, as well as at the $p \leq 0.05$ and $p \leq 0.01$ levels